The first human cell line-derived erythropoietin, epoetin-δ (Dynepo®), in the management of anemia in patients with chronic kidney disease

Clinical Nephrology

Volumn 68, Issue 1, 2007, Pages 26-31

  Martin, K J ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Anemia; Chronic kidney disease; Epoetin ; Hemoglobin

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD CLOTTING DISORDER; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEMUR TUMOR; FLU LIKE SYNDROME; HEART PALPITATION; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPERVOLEMIA; HYPOTENSION; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE REACTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SUBDURAL HEMATOMA; SUICIDE ATTEMPT; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE; VOMITING;

EID: 34447273146     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp68026     Document Type: Article

References (24)

1. Astor BC et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2006; 151: 492-500.
2. Avram MM et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin. Kidney Int. 2003; Suppl: S6-S11.
3. Bennet CL et al. Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005; 106: 3343-3347.
4. Bosman DR et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care. 2001; 24: 495-499.
5. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003; 18 (Suppl 8): viii37-41.
6. Castelli G et al. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human erythropoietin. Pharmacol Res. 2000; 41: 313-318.
7. Hokke CH et al. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett. 1990; 275: 9-14.
8. Jacobs C. Treatment of anemia in dialysis patients in France (1998-1999) (Study by ESAM-France). Nephrologie. 2002; 23: 85-91.
9. Li S et al. Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004; 65: 1864-1869.
10. Locatelli F et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004; 19: 121-132.
11. Macdougall IC. Hyporesponsiveness to anemia therapy - what are we doing wrong? Petit Dial Int. 2001; 21 (Suppl 3): S225-S230.
12. Macdougall IC. Poor response to erythropoietin. Br Med J. 1995; 310: 1424-1425.
13. McClellan W et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20: 1501-1510.
14. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant. 2002; 17 (Suppl 11): 44-46.
15. Santoro A. Anemia in renal insufficiency. Rev Clin Exp Hernatol. 2002; Suppl 1: 12-20.
16. Shahrokh Z, Flatman S, Davies M, Baycroft A, Heartlein M. Erythropoietin produced by a human cell line has only trace levels of potentially immunogenic N-glycolylneuraminic acid residues. Haematologica/Hematol J. 2006; 91 (Suppl 1): 208.
17. Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003; 18 (Suppl 2): ii7-12.
18. Skibeli V et al. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001; 98: 3626-3634.
19. Spinowitz BS, Pratt RD. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease. Curr Med Res Opin. 2006; 22: 2507-2513.
20. Stevens PE et al. Anaemia in patients with diabetes: unrecognised, undetected and untreated? Curr Med Res Opin. 2003; 19: 395-401.
21. Tangvoranuntakul P et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA. 2003; 100: 12045-12050.
22. Thomas MC et al. Anaemia in diabetes: is there a rationale to TREAT? Diabetologia. 2006; 49: 1151-1157.
23. Valderrabano F et al. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003; 18: 89-100.
24. Zhu A, Hurst R. Anti-N-glycolylneuraminic acid antibodies identified in healthy human serum. Xenotransplantation. 2002; 9: 376-381.